Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 4/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | GMNN | O75496 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 2/20 | 0.40 |
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | MMP2 | P08253 | 2/20 | 0.40 |
| ▸ | CA9 | Q16790 | 2/20 | 0.40 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27512417 | 1.00 | EPHX2 (0.46) | EPHX2TP53KDM4EGMNNLMNA | |
| SCHEMBL6681095 | 0.90 | TSHR (0.44) | EPHX2TP53KDM4ELMNAMAPT | |
| SCHEMBL10523056 | 0.81 | EPHX2 (0.49) | EPHX2TP53KDM4EGMNNLMNA | |
| SCHEMBL13681637 | 0.81 | CYP2D6 (0.47) | TP53KDM4EGMNNLMNAMAPT | |
| SCHEMBL5682017 | 0.81 | CYP2D6 (0.47) | TP53KDM4EGMNNLMNAMAPT | |
| SCHEMBL17865084 | 0.81 | EPHX2 (0.46) | EPHX2TP53SMN1; SMN2NPSR1CA12 | |
| SCHEMBL4821191 | 0.79 | EPHX2 (0.45) | EPHX2TP53NPSR1CA12CA1 | |
| SCHEMBL7233413 | 0.79 | TSHR (0.34) | — | |
| SCHEMBL14111950 | 0.78 | CTSK (0.41) | EPHX2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL5523650 | 0.78 | EPHX2 (0.44) | EPHX2TP53KDM4EGMNNLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103539640-A | Butylene type liquid crystal compound and preparation method of same | YANTAI VALIANT FINE CHEMICALS CO LTD | 2014-01-29 | — | — | CN | disclosed |
| US-20090247471-A1 | INHIBITORS OF CRUZIPAIN AND OTHER CYSTEINE PROTEASES | AMURA THERAPEUTICS LTD. (GB) | 2009-10-01 | — | — | US | disclosed |
| US-7425562-B2 | Inhibitors of cruzipain and other cysteine proteases | AMURA THERAPEUTICS LTD. (GB) | 2008-09-16 | — | — | US | disclosed |
| US-20080200467-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. | 2008-08-21 | — | — | US | disclosed |
| WO-2008073623-A2 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. (US) | 2008-06-19 | — | — | WO | disclosed |
| EP-1362052-B1 | INHIBITORS OF CRUZIPAIN AND OTHER CYSTEINE PROTEASES | AMURA THERAPEUTICS LTD (GB) | 2007-03-07 | — | — | EP | disclosed |
| US-7132449-B2 | Inhibitors of cruzipain and other cysteine proteases | AMURA THERAPEUTICS LIMITED (GB) | 2006-11-07 | — | — | US | disclosed |
| US-20040138250-A1 | Inhibitors of cruzipain and other cysteine proteases | GRUNENTHAL GMBH (DE) | 2004-07-15 | — | — | US | disclosed |
| US-20040127424-A1 | Inhibitors of cruzipain and other cysteine proteases | AMURA THERAPUTICS LIMITED (GB) | 2004-07-01 | — | — | US | disclosed |
| EP-1362052-A1 | INHIBITORS OF CRUZIPAIN AND OTHER CYSTEINE PROTEASES | Amura Therapeutics Limited (GB) | 2003-11-19 | — | — | EP | disclosed |
| EP-1358174-A2 | INHIBITORS OF CRUZIPAIN AND OTHER CYSTEINE PROTEASES | Amura Therapeutics Limited (GB) | 2003-11-05 | — | — | EP | disclosed |
| WO-2002057248-A2 | INHIBITORS OF CRUZIPAIN AND OTHER CYSTEINE PROTEASES | AMURA THERAPEUTICS LIMITED (GB) | 2002-07-25 | — | — | WO | disclosed |
| WO-2002057270-A1 | INHIBITORS OF CRUZIPAIN AND OTHER CYSTEINE PROTEASES | AMURA THERAPEUTICS LIMITED (GB) | 2002-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138250-A1 | Inhibitors of cruzipain and other cysteine proteases | CPN1, CTRL, CPA1 | EPHX2 1399/4885TP53 2563/4885KDM4E 4314/4885 |
| US-20040127424-A1 | Inhibitors of cruzipain and other cysteine proteases | CPN1, CTRL, CPA1 | EPHX2 1390/4885TP53 3139/4885KDM4E 4215/4885 |
| US-20090247471-A1 | INHIBITORS OF CRUZIPAIN AND OTHER CYSTEINE PROTEASES | CPN1, CTRL, CPA1 | EPHX2 1206/4885TP53 2060/4885KDM4E 4239/4885 |
| US-20080200467-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | EPHX1, EPHX2, NCEH1 | EPHX2 2/4885TP53 3408/4885KDM4E 905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.